The document summarizes a roundtable discussion on the relevance and sustainability of the DRIVE study platform. Representatives from DRIVE, ECDC, EMA, IMI discussed the main value of DRIVE in evaluating influenza vaccine effectiveness across Europe. Questions focused on governance barriers and improvements, the appropriate level of detail for vaccine effectiveness measures, increasing data capacity through open source and real-world evidence, and how to ensure long-term funding and governance structures. The panel will develop an executive summary of the discussion to be published on the DRIVE website.

1. Acknowledgement
DRIVE project has received funding from the Innovative Medicines Initiative 2
Joint Undertaking under grant agreement No 777363, This Joint Undertaking
receives support from the European Union’s Horizon 2020 research and
innovation programme and EFPIA.
Roundtable discussion:
Relevance of the DRIVE study platform
and sustainability
Javier Diez Domingo (FISABIO), Hanna Nohynek (THL) & Cédric Mahé (Sanofi Pasteur)
DRIVE Annual Forum
17th-18th July 2019, Helsinki

2. Acknowledgement
DRIVE project has received funding from the Innovative Medicines Initiative 2
Joint Undertaking under grant agreement No 777363, This Joint Undertaking
receives support from the European Union’s Horizon 2020 research and
innovation programme and EFPIA.
Panel of experts
ECDC (Pasi Penttinen),
EMA (Manuela Mura),
IMI (Tek-Ang LIM & Isabelle Bekeredjian-Ding)

3. Questions of interest
What is the main added value of DRIVE in the current European Influenza
vaccine effectiveness landscape and what is the role of your institution?
What are the main barriers of the current study platform governance? How
can we improve? (based on previous discussions)

4. Questions of interest
What level of granularity of Influenza Vaccine Effectiveness is meaningful
to consider?

5. Questions of interest
How should we increase the capacity of the study platform (volume of
data)?
- How should we promote open source? What is your institution’s
views about the open data model?
- Can we use secondary data /databases/Real World Evidence as
alternative data sources even at the cost of reliability, specificity and
timeliness?

6. Questions of interest
How can we make this model sustainable (funding, governance and host
institution)?

7. Development of an executive summary with the panel of experts
-> made publicly available on DRIVE website in September 2019
Next steps

8. Acknowledgement
DRIVE project has received funding from the Innovative Medicines Initiative 2
Joint Undertaking under grant agreement No 777363, This Joint Undertaking
receives support from the European Union’s Horizon 2020 research and
innovation programme and EFPIA.
Thank you